Target 2035 – an update on private sector contributions
Suzanne Ackloo, Albert A. Antolín, José M. Bartolomé, Hartmut Beck, Alex N. Bullock, Ulrich A. K. Betz, Jark Böttcher, Peter J. Brown, Menorca Chaturvedi, Alisa Crisp, Danette L. Daniels, Jan Dreher, Kristina Edfeldt, A.M. Edwards, Ursula Egner, Jonathan M. Elkins, Christian Fischer, Tine Glendorf, Steven D. Goldberg, Ingo V. Hartung, Alexander Hillisch, Evert Homan, Stefan Knapp, Markus Köster, Oliver Krämer, Josep Llaveria, Uta Lessel, S. Lindemann, Lars Linderoth, Hisanori Matsui, Maurice Michel, Florian Montel, Anke Mueller‐Fahrnow, Susanne Müller, Dafydd R. Owen, Kumar Singh Saikatendu, Vijayaratnam Santhakumar, Wendy E. Sanderson, Cora Scholten, Matthieu Schapira, Sujata Sharma, Brock T. Shireman, M. Sundström, Matthew H. Todd, Claudia Tredup, Jennifer D. Venable, Timothy M. Willson, C.H. Arrowsmith
Abstract
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging 'open' principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.